Here's why the Emyria (ASX:EMD) share price is up 17% to a record high

What did Emyria announce?

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Emyria Ltd (ASX: EMD) share price jumped to an all-time high today. This comes after the drug development and care delivery company announced a successful share placement by one of Australia's largest private investment groups.

During afternoon trade, Emyria shares accelerated to a record high of 39 cents apiece before retreating slightly to 38 cents, up 16.92% at the time of writing.

Emyria secures strategic investment

Investors appear excited about the company bringing its newest investor on board, sending the Emyria share price to uncharted territory.

According to its release, Emyria advised it has received a $5 million strategic investment from Tattarang through a share placement.

Owned by the Forrest family, namely Andrew 'Twiggy' Forrest, Tattarang holds an extensive investment portfolio. This includes sectors across agri-food, energy, resources, property, lifestyle and healthtech.

Tattarang and its related entities hold a 36% stake in Fortescue Metals Group Limited (ASX: FMG).

Under the placement, Emyria will issue 20 million shares to Tattarang at a price of 25 cents each. Once completed, this will give Tattarang a 7.3% interest in Emyria.

In addition to the placement, 10 million options will be issued at an exercise price of 40 cents per option. The expiry date is two years from the expected date of 24 November 2021.

The funds received will be allocated to Emyria's synthetic cannabinoid registration programs with the Therapeutic Goods Administration (TGA), and the United States Food and Drug Administration (FDA).

Furthermore, the company is also seeking to advance its novel MDMA-analogue development program with the University of Western Australia.

Emyria managing director, Dr Michael Winlo commented:

We are delighted to receive Tattarang's strong support with this placement.

Emyria is the only ASX-listed company that controls patient-treating clinics and a clinical-trial-grade data system and uses these assets to accelerate the development and registration of new drugs, digital technologies and care models.

Our current leading programs cover synthetic cannabinoid-based pharmaceuticals, MDMA-assisted therapy and novel psychedelic drug development. We are very pleased to welcome Tattarang to be part of this next phase of growth.

Emyria share price summary

Over the past 12 months, Emyria shares have registered gains of more than 400%, with year-to-date hovering above 300% in 2021.

Emyria presides a market capitalisation of roughly $58.52 million and has approximately 153.99 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a woman and a man sleep side by side with the woman placing a hand on the man's chest while he wears a sleep breathing machine.
Healthcare Shares

Do weight loss drugs pose a threat to ResMed shares?

It's a question being asked amongst investor circles in 2024.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Buy this high-flying ASX healthcare stock for market-beating returns

Bell Potter thinks this top stock could keep rising from where it trades today.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 66% in FY24, will Telix Pharmaceuticals shares continue?

After such an impressive run, has the trend exhausted?

Read more »

Man sleeping with a sleep apnoea mask on.
Healthcare Shares

Buy Resmed shares at 'attractive entry level' says top broker

Could this be the right entry point to own Resmed?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

CSL shares hit new 52-week high! What's next?

These ASX experts reckon CSL investors are still in for a treat.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

Read more »

Man pointing at a blue rising share price graph.
Healthcare Shares

Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

Read more »